Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?. (2nd December 2018)

• Record Type: Journal Article
• Authors: Huttner, Angela; Siegrist, Claire-Anne
• Is Part Of: Expert review of vaccines. Volume 17:Number 12(2018)
• Page Start: 1105
• Page End: 1110
• Publication Date: 2018-12-02
• Subjects: Ebola virus disease -- Ebola vaccine -- rVSV-ZEBOV vaccine -- immune response -- durability -- persistence -- seropositivity; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2018.1546582
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Introduction : The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown. Areas covered : We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. We also review determinants of initial responses and of their persistence. Expert commentary : Persistence of EBOV-GP-specific antibody responses is strong at 2 years – currently the longest post-vaccination interval studied – after a single injection. Vaccine dose predicts persistence of seropositivity, though the magnitude of antibody responses at later time points becomes less dose-dependent. Vaccine-related arthritis is a significant predictor of both persistence and magnitude of the antibody response.